naftopidil has been researched along with Nervous System Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araki, I; Gotoh, M; Homma, Y; Igawa, Y; Kakizaki, H; Nishizawa, O; Seki, N; Sugaya, K; Takeda, M; Takei, M; Yamanishi, T; Yokota, T; Yoshida, M | 1 |
1 trial(s) available for naftopidil and Nervous System Diseases
| Article | Year |
|---|---|
Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Naphthalenes; Nervous System Diseases; Piperazines; Receptors, Adrenergic, alpha-1; Rheology; Treatment Outcome; Urodynamics; Urologic Diseases; Young Adult | 2011 |